文献类型：期刊文献

英文题名：The role of serologic biomarkers "liquid biopsy '' in the fight against breast cancer: From biological foundations to clinical impact

作者：Li, Yan[1];Wang, Yi[2];Wang, Rongrong[2];Liu, Ying[3];Pei, Jianying[3]

第一作者：Li, Yan

通信作者：Pei, JY[1]

机构：[1]Northwest Minzu Univ, Med Coll, Dept Biochem & Mol Biol, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Sch Publ Hlth, Lanzhou, Gansu, Peoples R China;[3]Gansu Prov Matern & Child Care Hosp, Dept Clin Lab Ctr, Lanzhou, Gansu, Peoples R China

第一机构：Northwest Minzu Univ, Med Coll, Dept Biochem & Mol Biol, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Matern & Child Care Hosp, Dept Clin Lab Ctr, Lanzhou, Gansu, Peoples R China.

年份：2026

卷号：29

期号：8

外文期刊名：ISCIENCE

收录：;Scopus(收录号：2-s2.0-105044239752);WOS:【SCI-EXPANDED(收录号:WOS:001823308000001)】；

基金：This work was supported by grants from the National Natural Science Foundation of China (grant no.: 82360469), grants from the Natural Science Foundation of Gansu Province (24JRRA937, 25JRRA1301), the Excellent Introduced Talents and Doctoral Startup Fund Project of Gansu Provincial Maternity and Child Care Hospital (GMCCH2024-2-7), the Talent Training Project of Gansu Provincial Maternity and Child Care Hospital (GMCCH2025-2-3-04), the Excellent Introduced Talents and Doctoral Startup, and the Major Project of Scientific and Technological Innovation in Gansu Provincial Health Industry (GSWSQNPY2025-12). All images were created in BioRender (BioRender.com).

语种：英文

外文关键词：Artificial intelligence; breast cancer; circulating tumor DNA; Diagnostics; health equity; liquid biopsy; minimal residual disease; Oncology; precision medicine; Therapeutics

摘要：Liquid biopsy, analyzing circulating tumor-derived components, including ctDNA, circulating tumor cells, microRNAs, and exosomes, has emerged as a key tool in precision oncology. This review synthesizes evidence from the past five years, covering biological mechanisms, analytical platforms, clinical applications, and implementation barriers. Evidence from multiple clinical studies suggests ctDNA shows higher sensitivity for metastatic disease monitoring than conventional biomarkers such as CA15-3 and circulating tumor cells. For minimal residual disease detection, tumor-informed assays demonstrate sensitivity of 88%-100% and provide a median lead time of 8-15 months before clinical relapse. Despite these advances, early-stage cancer detection remains suboptimal, cost-effectiveness evidence is limited, and disparities in access are increasing. We critically evaluate current technologies and translational gaps and highlight the need for standardized clinical integration pathways. Overall, liquid biopsy is transitioning from a complementary diagnostic tool toward a longitudinal framework for cancer management, although substantial methodological and systemic challenges remain.